Glaxosmithkline Pharmaceuticals Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/qshy14u0fs89hmu9s95eikgn.pdf

Key Takeaways


General Medicines: The Recovery Quarter

Bhushan Akshikar: "I think our ability to therefore hold and deliver consistent performance quarter after quarter is more important than having a flash in the pan."

Specialty & Oncology: Building the Next Growth Engine

Bhushan Akshikar: "It's one of the few or probably the only one, which has got well-articulated and established documented overall survival benefit."

Vaccines: Double-Digit Growth and an Adult Franchise Building


Pipeline & Launch Intent: The Five-Year Build

Bhushan Akshikar: "We have the next generation of ADCs as they're called, antibody drug conjugates. So those are clearly a part of the remit that we have for India."

Margins: Sustaining, Not Expanding

Bhushan Akshikar: "Our objective will be to hold and sustain these margins which we've worked to deliver over the last three years. So that would be the objective rather than expanding gross margin any more or expanding the EBITDA."

Growth Ambition & Market Context

Bhushan Akshikar: "This organization has to grow in the range of 12% to 13% annually over the next five years so that we can double the business from where we were in '23-'24 to the point of becoming an INR8,000 crores business."

Guidance & Commitments

CommitmentSpecificsTimeline
Supply normalizationNo more supply constraints from the CMO fire impactFrom Q4 FY26 onwards
Blenrep (belantamab) launchLaunch for multiple myeloma in IndiaComing financial year, probably Q2 or Q3
Haematology team launchDedicated field force for blood cancers, beginning with multiple myelomaComing weeks and months
Five-year growth target12-13% annual revenue growth to double business to INR8,000 croresOver five years from FY23-24 base
Margin objectiveHold and sustain margins delivered over last three years; no expansion targetedOngoing
Freshness index10-15% target for coming financial year; 20-25% over longer horizonComing financial year / 5-7 years

Key Metrics

MetricQ3 FY26
Standalone revenue₹1,000 cr+, +8.1% YoY; first quarter crossing this milestone
Consolidated revenue growth~10% YoY
EBITDA margin35.9%, +520 bps YoY; EBITDA growth of 26.7%
PAT margin27.3%, +290 bps YoY
EPS growth+9% YoY
Cash position₹2,426 cr
One-off labour cost impact₹11.8 cr, included in employee expenses
General medicines revenue share>75%–78% of topline
Pediatric vaccines growth+11% YoY, led by Boostrix, Varilrix, Havrix growing double digits
Shingrix annual value₹70–75 cr on a calendar year basis; ~100,000 doses sold in CY2025
Nucala patient run-rate~100 patients per month in Q3
Digital touch points~0.4 cr for the quarter, including face-to-face interactions
Total employees~3,000; sales field force of ~2,000
Portfolio under NLEM price control35%–38% of overall portfolio
Oncology key account specialists~25, covering 850–1,000 oncologists